Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

  • There is currently no data for BIOM

Trading Update

25 Apr 2013 07:00

RNS Number : 1743D
Biome Technologies PLC
25 April 2013
 



25 April 2013

 

Biome Technologies plc

("Biome", "the Company" or "the Group")

 

Trading Update

 

In advance of its Annual General Meeting today, Biome Technologies plc is pleased to announce its trading update for the three months ended 31 March 2013.

 

Trading Update

Total Group revenues achieved for the first three months of the year were £0.4m (Q1 2012: £4.6m including contributions from Biotec). We anticipate performance this year to be second half weighted and consequently expect sales growth to increase in both divisions as the year progresses.

 

The Group's cash position at 31st March 2013 was £5.8m (31st December 2012: £6.3m).

 

We continue to make progress with the strategy, as set out at our full year results, to commercialise and develop wholly owned intellectual property. and our performance remains in line with the Board's expectations.

 

Bioplastics Division

Q1 2013 revenues were £0.2m (Q1 2012: £4.3m including contributions from Biotec). This division is focused on developing high margin, application led products with enhanced level of functionality. Two key projects currently being undertaken include single use foodservice products and single use coffee capsules. These projects are progressing well and their contribution to revenues will become clearer during the second half of the year when they are expected to pass into a predominantly manufacturing phase.

 

In the first quarter, the division was awarded a grant by the Government-backed Technology Strategy Board (TSB) to investigate a bio-based alternative for the oil derived organic chemicals used in the manufacture of bioplastics. The £150,000 grant has been made to Biome Technologies as part of the TSB's 'Sustainable high value chemical manufacture through industrial biotechnology' competition, which funds projects that apply sustainable biobased feedstocks and biocatalytic processes for the production of chemicals. Biome has partnered with the University of Warwick's Centre for Biotechnology and Biorefining to work on the feasibility study that will be funded by this grant.

 

Stanelco RF Technologies Division

Q1 revenues were £0.2m (Q1 2012: £0.3m). This Division continues to see a wider variety of opportunities opening up as the business develops. As previously reported, a number of optical fibre furnace deliveries have been delayed due to some uncertainties in the Chinese fibre market although this market is expected to return to growth during the course of the year. Progress continues on the Durapipe project and the timing of delivery for ten pre-production units will be finalised over the next quarter, following time-based testing of the final pipe-work.

 

Stephen Baskerville, will be joining the Group to head up the Division as its Managing Director in August. Stephen joins the business following some twenty years in technical and commercial roles within the industry, most recently as Director of Heating Products at Inductotherm Heating and Welding Limited, a subsidiary of the global Inductotherm Group.

 

 

- Ends -

 

 

 

For further information please contact:

 

Biome Technologies plc

Paul Mines, Chief Executive Officer

www.biometechnologiesplc.com Tel: +44 (0) 2380 867 100

 

 

Daniel Stewart & Company plc

David Hart

www.danielstewart.co.uk Tel: +44 (0) 20 7776 6550

 

First Columbus

Chris Crawford/Kelly Gardiner

www.first-columbus.com Tel: +44 (0) 20 3002 2070

 

 

FTI Consulting

Oliver Winters/Latika Shah Tel: +44 (0) 20 7831 3113

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTNKQDKFBKDDQB
Date   Source Headline
27th Apr 20071:34 pmRNSResult of AGM
27th Apr 20071:32 pmRNSDirectorate Change
26th Apr 20071:42 pmRNSAnnual Information Update
13th Apr 200712:29 pmRNSDirector's Dealing
30th Mar 20071:32 pmRNSAnnual Report and Accounts
23rd Mar 20075:09 pmRNSNotifiable Interest
21st Mar 20077:03 amRNSPreliminary Results
14th Mar 20075:59 pmRNSHolding(s) in Company
26th Feb 20077:01 amRNSBoard Appointment
23rd Feb 20073:18 pmRNSHolding(s) in Company
30th Jan 20079:00 amRNSNotice of Results
18th Dec 20064:58 pmRNSTotal Voting Rights
8th Dec 200612:31 pmRNSNotifiable Interest
28th Nov 20063:32 pmRNSNotifiable Interest
17th Nov 20063:33 pmRNSNotifiable Interest
16th Nov 20069:02 amRNSNotifiable Interest
14th Nov 20064:37 pmRNSDirectorate Change
14th Nov 20064:09 pmRNSDirector/PDMR Shareholding
14th Nov 20064:03 pmRNSNotifiable Interest
14th Nov 20069:55 amRNSNotifiable Interest
10th Nov 200610:29 amRNSHolding(s) in Company
9th Nov 200611:45 amRNSNotifiable Interest
8th Nov 20063:08 pmRNSNotifiable Interest
7th Nov 20068:01 amRNSIssue of Equity
6th Nov 200612:12 pmRNSResult of EGM
3rd Nov 20064:41 pmRNSNotifiable Interest
3rd Nov 20061:17 pmRNSOpen Offer Result - Amendment
2nd Nov 20066:03 pmRNSOpen Offer Result
31st Oct 200611:54 amRNSNotifiable Interest
17th Oct 20065:54 pmRNSNotifiable Interest
17th Oct 200610:44 amRNSNotifiable Interest
16th Oct 20063:17 pmRNSNotifiable Interest
12th Oct 200612:35 pmRNSDoc re. Posting of Prospectus
11th Oct 20061:09 pmRNSNotifiable Interest
9th Oct 200611:13 amRNSProposed Placing & Open Offer
5th Oct 200610:25 amRNSFinancing Update
3rd Oct 200612:56 pmRNSStatement re. Press Comment
2nd Oct 20064:41 pmRNSSecond Price Monitoring Extn
2nd Oct 20064:35 pmRNSPrice Monitoring Extension
8th Sep 20067:01 amRNSTrading Statement
17th Aug 20067:44 amRNSTrading Statement
16th Aug 20065:52 pmRNSAdditional Listing - AMEND
14th Aug 200611:55 amRNSAdditional Listing
10th Aug 200612:25 pmRNSRe Contract
14th Jul 20067:56 amRNSInterim Results - Replacement
14th Jul 20067:00 amRNSInterim Results
2nd Jun 200611:26 amRNSNew Ord Share Placing-Amendmt
2nd Jun 20068:45 amRNSNew Ordinary Share Placing
25th May 20067:02 amRNSWrap 100 FDA approval
16th May 200610:43 amRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.